Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 11;12(3):257. doi: 10.1038/s41419-021-03522-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 8 — A, B Growth curves of A549 (A) and H520 (B) engraftments treated with 800 μg/mouse 1B50-1, 1.5 mg/kg carboplatin (CBP), or the combination of both, every other day after the tumors were visible. C, D The histograms showing the average weight of the dissected tumors of A549 (C) and H520 (D) engraftments treated with indicated regimens. E, F Photographs of the dissected tumors of A549 (E) and H520 (F) engraftments received the indicated treatments. (G) Growth curves of one NSCLC PDX tumors i.p. injected with 1B50-1, CBP, or the combination of both. H Histogram demonstrates the percentage of α2δ1⁺ cells in the residual tumors of A549 xenografts received the indicated treatment as detected by flow cytometry. I Dissected tumors showing the tumor-initiating ability of the A549 engraftment residues after each drug treatment, which was assayed by re-transplanting 10⁴ cells per site with Matrigel into NOD/SCID mice. Scale bars, 5 cm. All error bars indicate SD. *p ≤ 0.05, compared with vehicle control group. Student’s t-test.